TY - JOUR AU - Singal, A. K. AU - Anand, B. S. PY - 2009 DA - 2009// TI - Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review JO - World J Gastroenterol VL - 15 UR - https://doi.org/10.3748/wjg.15.3713 DO - 10.3748/wjg.15.3713 ID - Singal2009 ER - TY - JOUR AU - Vogel, M. AU - Rockstroh, J. K. PY - 2007 DA - 2007// TI - Hepatotoxicity and liver disease in the context of HIV therapy JO - Curr Opin HIV AIDS VL - 2 UR - https://doi.org/10.1097/COH.0b013e3281ca6fd2 DO - 10.1097/COH.0b013e3281ca6fd2 ID - Vogel2007 ER - TY - JOUR AU - Walker, U. A. PY - 2007 DA - 2007// TI - Antiretroviral therapy-induced liver alterations JO - Curr Opin HIV AIDS VL - 2 UR - https://doi.org/10.1097/COH.0b013e328122dbaa DO - 10.1097/COH.0b013e328122dbaa ID - Walker2007 ER - TY - JOUR AU - Sulkowski, M. S. AU - Mehta, S. H. AU - Chaisson, R. E. AU - Thomas, D. L. AU - Moore, R. D. PY - 2004 DA - 2004// TI - Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir JO - AIDS VL - 18 UR - https://doi.org/10.1097/00002030-200411190-00008 DO - 10.1097/00002030-200411190-00008 ID - Sulkowski2004 ER - TY - JOUR AU - Pineda, J. A. AU - Pérez-Elías, M. J. AU - Peña, J. M. AU - Luque, I. AU - Rodríguez-Alcantara, F. PY - 2008 DA - 2008// TI - Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens JO - HIV Clin Trials VL - 9 UR - https://doi.org/10.1310/hct0905-309 DO - 10.1310/hct0905-309 ID - Pineda2008 ER - TY - JOUR AU - Jevtovic, D. j. AU - Ranin, J. AU - Salemovic, D. PY - 2008 DA - 2008// TI - The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART JO - Biomed Pharmacother VL - 62 UR - https://doi.org/10.1016/j.biopha.2006.12.005 DO - 10.1016/j.biopha.2006.12.005 ID - Jevtovic2008 ER - TY - JOUR AU - Pineda, J. A. AU - Santos, J. AU - Rivero, A. AU - Abdel-Kader, L. AU - Palacios, R. AU - Camacho, A. AU - Lozano, F. AU - Macías, J. PY - 2008 DA - 2008// TI - Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis JO - J Antimicrob Chemother VL - 61 UR - https://doi.org/10.1093/jac/dkn045 DO - 10.1093/jac/dkn045 ID - Pineda2008 ER - TY - JOUR AU - Grinsztejn, B. AU - Nguyen, B. Y. AU - Katlama, C. AU - Gatell, J. M. AU - Lazzarin, A. AU - Vittecoq, D. PY - 2007 DA - 2007// TI - Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518. in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60597-2 DO - 10.1016/S0140-6736(07)60597-2 ID - Grinsztejn2007 ER - TY - JOUR AU - Croxtall, J. D. AU - Keam, S. J. PY - 2009 DA - 2009// TI - Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients JO - Drugs VL - 69 UR - https://doi.org/10.2165/00003495-200969080-00007 DO - 10.2165/00003495-200969080-00007 ID - Croxtall2009 ER - TY - JOUR AU - Steigbigel, R. T. AU - Cooper, D. A. AU - Kumar, P. N. AU - Eron, J. E. AU - Schechter, M. AU - Markowitz, M. PY - 2008 DA - 2008// TI - Raltegravir with optimized background therapy for resistant HIV-1 infection JO - N Engl J Med VL - 24 UR - https://doi.org/10.1056/NEJMoa0708975 DO - 10.1056/NEJMoa0708975 ID - Steigbigel2008 ER - TY - JOUR AU - Núñez, M. J. AU - Martín-Carbonero, L. AU - Moreno, V. AU - Valencia, E. AU - Garcia-Samaniego, J. AU - Castillo, J. G. AU - Barreiro, P. AU - González-Lahoz, J. AU - Soriano, V. PY - 2006 DA - 2006// TI - Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients JO - AIDS Res Hum Retroviruses VL - 22 UR - https://doi.org/10.1089/aid.2006.22.825 DO - 10.1089/aid.2006.22.825 ID - Núñez2006 ER - TY - JOUR AU - Palacios, R. AU - Vergara, S. AU - Rivero, A. AU - Aguilar, I. AU - Macías, J. AU - Camacho, A. AU - Lozano, F. AU - García-Lázaro, M. AU - Pineda, J. A. AU - Torre-Cisneros, J. AU - Márquez, M. AU - Santos, J. PY - 2006 DA - 2006// TI - Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir JO - HIV Clin Trials VL - 7 UR - https://doi.org/10.1310/hct0706-319 DO - 10.1310/hct0706-319 ID - Palacios2006 ER - TY - JOUR AU - Meraviglia, P. AU - Schiavini, M. AU - Castagna, A. AU - Viganò, P. AU - Bini, T. AU - Landonio, S. AU - Danise, A. AU - Moioli, M. C. AU - Angeli, E. AU - Bongiovanni, M. AU - Hasson, H. AU - Duca, P. AU - Cargnel, A. PY - 2004 DA - 2004// TI - Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation JO - HIV Med VL - 5 UR - https://doi.org/10.1111/j.1468-1293.2004.00232.x DO - 10.1111/j.1468-1293.2004.00232.x ID - Meraviglia2004 ER - TY - CHAP AU - Vispo, E. AU - Mena, A. AU - Maida, I. AU - Blanco, F. AU - Cordoba, M. AU - Labarga, P. PY - 2009 DA - 2009// TI - Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C BT - J Antimicrob Chemother ID - Vispo2009 ER -